Message :
Required fields
Achieved primary endpoint demonstrating significant correlation between DetermaIO and two-year overall survival rate to atezolizumab in metastatic bladder cancer
DetermaIO identified additional immunotherapy responsive patients missed by commonly used biomarkers
Data supports potential utility of DetermaIO test across multiple solid tumors as predictor of response to Immune Checkpoint Inhibitor therapy in estimated $3 billion market in the United States
KOL Webinar discussing results to be held on April 19 at 11:30 AM EDT/8:30 AM PDT
IRVINE, Calif., April 10, 2021 (GLOBE NEWSWIRE) Oncocyte Corporation (Nasdaq: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the cancer care continuum, presented new data at the American Association for Cancer Research (AACR) Annual Meeting 2021, being held virtually from April 10-15, 2021. The presentations featured studies of Oncocyte’s novel
Oncocyte Presents New Data at 2021 American Association for Cancer Research Annual Meeting apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.